Acquisitions Help Valeant Pharma Rise To The Top
Chasing growth leads most drug companies with a choice: Either come up with exciting new treatments to ease humanity's suffering (that takes years and lots of money) or buy companies that already have done so. Some drugmakers do both. Canadian drugmaker Valeant Pharmaceuticals (VRX) has a track record of aggressive acquisitions. Its latest was announced Sept. 3. Valeant will pay $2.6 billion for Medicis Pharmaceutical (MRX). The deal should bring
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here